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Identity 
Other names: DBC-1; DBC1; NET35; p30DBC 




This gene can be found on chromosome 8 at location 
22462539-22477984. 
 
Adapted from http://genome.ucsc.edu. 










The DNA sequence contains 21 exons and the 




Human KIAA1967/p30 DBC encodes a 923 amino 
acids protein with a leucine zipper motif, a Nudix 
domain, an EF hand motif and a coiled coil domain. 
Expression 
KIAA1967/p30 DBC is widely expressed in multiple 
tissues. 
Localisation 
p30 DBC has a nuclear localization motif and localizes 
in the nucleus. 
Function 
p30 DBC is an endogenous inhibitor of the class III 
protein deacetylase SIRT1. p30 DBC directly interacts 
with the catalytic domain of SIRT1 and inhibits the 
deacetylase activity of SIRT1. In doing so, p30 DBC 
promotes the acetylation of SIRT1 substrates such as 
p53 and FOXO3 following cellular stress in several 
cancer cell lines and inhibits SIRT1-dependent cell 
survival. 
p30 DBC inhibits the activity of SUV39H1 
methyltransferase and regulate heterochromatin 
formation via its inhibitory effect toward both SIRT1 
and SUV39H1. 
p30 DBC contains the Nudix hydrolase (MutT) 
domain, which is predicted to bind nucleoside 
diphosphate sugars and nicotinamide adenine 
dinucleotide (NAD), a co-substrate for SIRT1 enzyme. 
However, the Nudix domain of p30 DBC is predicted 
to be catalytically inactive. 
In response to apoptosis-inducing signals, such as 
exposure to TNFalpha, etoposide or staurosporine, p30 
DBC is cleaved into C-terminal p120 and p66 
fragments in a caspase-dependent manner. The C-
terminal fragment then relocalizes from nucleus to 
cytosol and mitochondria, and sensitizes cells to 
apoptotic stimuli. These findings suggest that p30 DBC 
promotes apoptosis through a positive feedback 
mechanism, which might suppress tumorigenesis by 
facilitating cell death in response to cellular stre ses. 
p30 DBC was found to act as a transcriptional 
coactivator of retinoic acid receptor alpha (RARalph ).  
The induction of RARalpha target genes such as Sox9 
and HoxA1 gene in response to retinoic acid requires 
p30 DBC in MCF-7 breast cancer cells. This 
transcriptional activity of p30 DBC is not affected by 
SIRT1 inhibitor nicotinamide, suggesting that at least 
this transcriptional regulation function of p30 DBC is 
independent of SIRT1. 
The first 150 amino acids of p30 DBC has been shown 
to interact with ERalpha through its hormone-binding 
domain in an estrogen-independent manner. The 
interaction between p30 DBC and ERalpha could 
stabilize ERalpha and promote breast cancer cell 
survival. 
In addition to regulating ERalpha activity, p30 DBC 
could also act as an androgen receptor (AR) 
coactivator. The ligand binding domain (LBD) of AR 
interacts with the N-terminus of p30 DBC (residues 
1~265) in the presence of AR ligand. This interaction 
enhances AR-DNA binding and facilitates AR's 
transcriptional activity. Knocking-down of p30 DBC 
decreases the induction of AR target genes including 
prostate specific antigen (PSA) in LNCaP prostate 
cancer cells. 
Homology 
Homologs were found in mammals. No p30 DBC 
homologs was identified in lower organism so far. 
Implicated in 
Breast and prostate carcinomas 
Note 
p30 DBC was initially identified to be downregulated 
in some breast and lung cancer specimens. However, in 
contrast to these findings, several microarray studies 
showed that p30 DBC mRNA is upregulated in breast 
cancers. In addition, p30 DBC1 could enhance ERalpha 
and AR signaling and promotes breast and prostate 
cancer cell proliferation. Therefore, p30 DBC gene 
could play a role in tumorigenesis based on in vitro 
studies, however, its function in cancer etiology remain 
to be verified in vivo. 
Prognosis 
High expression of p30 DBC is associated with poor 
prognosis and metastasis of breast carcinoma. 
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